CN111388670A - Synthesis method of mineralized Prussian blue-light immune preparation based on lipopolysaccharide - Google Patents
Synthesis method of mineralized Prussian blue-light immune preparation based on lipopolysaccharide Download PDFInfo
- Publication number
- CN111388670A CN111388670A CN202010203820.6A CN202010203820A CN111388670A CN 111388670 A CN111388670 A CN 111388670A CN 202010203820 A CN202010203820 A CN 202010203820A CN 111388670 A CN111388670 A CN 111388670A
- Authority
- CN
- China
- Prior art keywords
- prussian blue
- solution
- potassium ferrocyanide
- light
- lipopolysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01C—AMMONIA; CYANOGEN; COMPOUNDS THEREOF
- C01C3/00—Cyanogen; Compounds thereof
- C01C3/08—Simple or complex cyanides of metals
- C01C3/12—Simple or complex iron cyanides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/10—Halides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to a method for synthesizing a mineralized Prussian blue-light immune preparation based on lipopolysaccharide, which comprises the steps of 1) weighing and preparing 1.0mM ferric trichloride hexahydrate aqueous solution and 1.0mM potassium ferrocyanide aqueous solution, 2)) and utilizing normal-temperature biomimetic synthesis of Prussian blue-light immune agent (L PS @ PB) nanoparticles, L PS can efficiently activate M1 type macrophages, further induce a large amount of inflammatory factors to activate a whole immune system and cause immune response, and the Prussian blue nanoparticle-guided MRI imaging guidance realizes light-operated release of tumor antigens, further enhances ICD effect and efficiently kills tumors.
Description
Technical Field
The invention relates to the field of preparation of Prussian blue-light immunizing agents, and in particular relates to a synthetic method for biomimetically synthesizing a Prussian blue-light immunizing agent based on lipopolysaccharide.
Background
Malignant tumor (cancer) has become one of the major public health problems seriously threatening the health of Chinese population, and the incidence of malignant tumor is continuously increasing in recent ten years according to the latest statistical data, and the prevention and control situation is increasingly severe. Therefore, the development cost is low and the response measures with good effect are not slow enough.
Recently, immunotherapy for tumor has been developed, which refers to a new direction of tumor therapy that applies immunological principles and methods to increase immunogenicity of tumor cells and sensitivity to killing by effector cells, stimulate and enhance anti-tumor immune response of the body, and deliver immune cells or effector molecules into the body of a patient, in conjunction with the killing of tumor cells by the immune system of the body, and inhibit tumor growth, with few side effects to the human body, L PS is a complex of lipid and polysaccharide, a chemical component unique to the outer wall of gram-negative bacteria, having a molecular weight greater than 10000, consisting of core polysaccharide, O-polysaccharide side chain, and lipid a, when cells are stimulated by L PS, L PS activates nuclear transcription factor NF- κ B through T L R4 on the surface of macrophages, and is classical, thus producing inflammation with the expression of cytokines, including TNT- α, I L-6, and I L-1 α, etc., and can highly express Inducible Nitric Oxide Synthase (iNOS), natural immunity, which can be used as an immune preparation for tumor therapy.
Photothermal therapy (PTT) is a diagnosis and treatment method accompanied by light, has the advantages of minimal invasion, high efficiency, good specificity, space-time controllability and the like, and is an ideal method for treating cancers. During treatment, it can destroy cell membranes within minutes using photothermal conversion, thereby killing cancer cells. The photothermal therapy process has less side effect, low systemic toxicity, no damage to normal tissue and great clinical application potential. If the photothermal therapy and the tumor immunotherapy are combined, the tumor therapy effect is greatly enhanced, and the tumor therapy is more thorough.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a Prussian blue-light immunizing agent (L PS @ PB) biomimetically synthesized based on lipopolysaccharide.
A synthetic method for biomimetically synthesizing a Prussian blue-light immunizing agent (L PS @ PB) based on lipopolysaccharide comprises the following steps:
1) 13.5mg of copper chloride dihydrate was weighed, and dissolved by ultrasonic waves after adding 50m L ultrapure water to obtain an aqueous ferric chloride hexahydrate solution having a concentration of 1.0 to 2.0 mM.
2) 21.1mg of gadolinium chloride hexahydrate was weighed, and dissolved by ultrasonic waves after adding 50m L ultrapure water to obtain a 1.0-2.0mM potassium ferrocyanide aqueous solution.
3) The method for biomimetically synthesizing L PS @ PB nanoparticles at normal temperature comprises the following steps:
(1) measuring 20m L ferric chloride hexahydrate solution on a temperature control stirring table, stirring and heating at 60 DEG C
(2) Measuring 20m of L potassium ferrocyanide solution, placing on a temperature-controlled stirring table, stirring and heating at 60 DEG C
(3) After 10 minutes, respectively adding 2-6mg of L PS into the solution, and reacting for 1 hour;
(4) adding a reaction solution of ferric trichloride hexahydrate and L PS into a reaction solution of potassium ferrocyanide and L PS by using a pipette, and reacting for 30 min;
(5) and then cooling the system to room temperature, washing and purifying the system for three times by using ethanol and deionized water, and re-dissolving the precipitate in the deionized water for later use.
The prepared medicine has the following advantages that 1) L PS can efficiently activate M1 type macrophages, further induce a large amount of inflammatory factors to activate the whole immune system and cause immune response, and 2) Prussian blue nanoparticle-guided MRI imaging visualization guidance realizes the light-operated release of tumor antigens, further enhances the ICD effect, induces an organism to generate an immunological memory function, and achieves the purpose of efficiently and thoroughly treating tumors.
Detailed Description
The present invention will be further described below.
Example 1:
1) 13.5mg of copper chloride dihydrate was weighed, and 50m of L mM ultrapure water was added thereto and dissolved by ultrasonic waves to obtain a 1.0mM aqueous solution of ferric chloride hexahydrate.
2) 21.1mg of gadolinium chloride hexahydrate was weighed, and dissolved by ultrasonic waves after adding 50m L ultrapure water to obtain a 1.0mM potassium ferrocyanide aqueous solution.
3) The method for biomimetically synthesizing L PS @ PB nanoparticles at normal temperature comprises the following steps:
(1) the ferric chloride hexahydrate solution with the concentration of 20m L was weighed on a temperature-controlled stirring table and stirred and heated at 60 ℃.
(2) A20 m potassium ferrocyanide solution with the concentration of L is weighed and placed on a temperature-controlled stirring table, and stirred and heated at the temperature of 60 ℃.
(3)3) after 10 minutes, 2mg of L PS was added to the above solutions, respectively, and reacted for 1 hour.
(4) Adding the reaction solution of ferric trichloride hexahydrate and L PS into the reaction solution of potassium ferrocyanide and L PS by using a pipette gun, and reacting for 30 min.
(5) And then cooling the system to room temperature, washing and purifying the system for three times by using ethanol and deionized water, and re-dissolving the precipitate in the deionized water for later use.
Example 2:
1) 27mg of copper chloride dihydrate was weighed, and 50m of L mM ultrapure water was added thereto and dissolved by ultrasonic waves to obtain a 2.0mM aqueous solution of ferric chloride hexahydrate.
2) 42.2mg of gadolinium chloride hexahydrate was weighed, and dissolved by ultrasonic waves after adding 50m L ultrapure water to obtain a potassium ferrocyanide aqueous solution having a concentration of 2.0 mM.
3) The method for biomimetically synthesizing L PS @ PB nanoparticles at normal temperature comprises the following steps:
(1) the ferric chloride hexahydrate solution with the concentration of 20m L was weighed on a temperature-controlled stirring table and stirred and heated at 60 ℃.
(2) A20 m potassium ferrocyanide solution with the concentration of L is weighed and placed on a temperature-controlled stirring table, and stirred and heated at the temperature of 60 ℃.
(3) After 10 minutes, 4mg of L PS was added to each of the above solutions and reacted for 1 hour.
(4) Adding the reaction solution of ferric trichloride hexahydrate and L PS into the reaction solution of potassium ferrocyanide and L PS by using a pipette gun, and reacting for 30 min.
(5) And then cooling the system to room temperature, washing and purifying the system for three times by using ethanol and deionized water, and re-dissolving the precipitate in the deionized water for later use.
Example 3:
1) 40.5mg of copper chloride dihydrate was weighed, and 50m of L mM ultrapure water was added thereto and dissolved by ultrasonic waves to obtain a 1.0mM ferric trichloride hexahydrate aqueous solution.
2) 63.3mg of gadolinium chloride hexahydrate was weighed, and dissolved by ultrasonic waves after adding 50m L ultrapure water to obtain a 1.0mM potassium ferrocyanide aqueous solution.
3) The method for biomimetically synthesizing L PS @ PB nanoparticles at normal temperature comprises the following steps:
(1) the ferric chloride hexahydrate solution with the concentration of 20m L was weighed on a temperature-controlled stirring table and stirred and heated at 60 ℃.
(2) A20 m potassium ferrocyanide solution with the concentration of L is weighed and placed on a temperature-controlled stirring table, and stirred and heated at the temperature of 60 ℃.
(3) After 10 minutes, 6mg of L PS was added to each of the above solutions, and the reaction was carried out for 1 hour.
(4) Adding the reaction solution of ferric trichloride hexahydrate and L PS into the reaction solution of potassium ferrocyanide and L PS by using a pipette gun, and reacting for 30 min.
(5) And then cooling the system to room temperature, washing and purifying the system for three times by using ethanol and deionized water, and re-dissolving the precipitate in the deionized water for later use.
Claims (1)
1. The method for synthesizing the mineralized Prussian blue-light immune preparation based on lipopolysaccharide is characterized by comprising the following steps of:
1) weighing copper chloride dihydrate, adding ultrapure water, and performing ultrasonic dissolution to obtain ferric chloride hexahydrate aqueous solution with the concentration of 1.0-2.0 mM;
2) weighing gadolinium chloride hexahydrate, adding ultrapure water, and performing ultrasonic dissolution to obtain a potassium ferrocyanide aqueous solution with the concentration of 1.0-2.0 mM;
3) the method for biomimetically synthesizing L PS @ PB nanoparticles at normal temperature comprises the following steps:
(1) measuring 20m L ferric chloride hexahydrate solution on a temperature control stirring table, and stirring and heating at 60 ℃;
(2) weighing 20m L potassium ferrocyanide solution, placing on a temperature-controlled stirring table, and stirring and heating at 60 ℃;
(3) after 10 minutes, respectively adding 2-6mg of L PS into the solution for reaction;
(4) adding a reaction solution of ferric trichloride hexahydrate and L PS into a reaction solution of potassium ferrocyanide and L PS by using a pipette, and reacting for 30 min;
(5) and then cooling the system to room temperature, washing and purifying the system for three times by using ethanol and deionized water, and re-dissolving the precipitate in the deionized water for later use.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010203820.6A CN111388670A (en) | 2020-03-20 | 2020-03-20 | Synthesis method of mineralized Prussian blue-light immune preparation based on lipopolysaccharide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010203820.6A CN111388670A (en) | 2020-03-20 | 2020-03-20 | Synthesis method of mineralized Prussian blue-light immune preparation based on lipopolysaccharide |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111388670A true CN111388670A (en) | 2020-07-10 |
Family
ID=71417248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010203820.6A Pending CN111388670A (en) | 2020-03-20 | 2020-03-20 | Synthesis method of mineralized Prussian blue-light immune preparation based on lipopolysaccharide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111388670A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113633769A (en) * | 2021-01-11 | 2021-11-12 | 重庆医科大学 | Preparation method and application of lipopolysaccharide-loaded composite nanoparticles |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784979A (en) * | 2014-01-17 | 2014-05-14 | 福州市传染病医院 | AntiGPC3-PB NPs (antiglypican3-Prussian Blue Nanoparticles) for photothermal therapy and magnetic resonance imaging of liver cancer as well as preparation and application thereof |
CN108495931A (en) * | 2015-11-11 | 2018-09-04 | 朱正崙 | A method of changing macrophage differentiation and is immunized |
CN110179837A (en) * | 2019-05-08 | 2019-08-30 | 天津大学 | The synthetic method of the visualization guidance tumour combined immunization treatment nanometer formulation of Gd:CuS mineralising influenza virus |
-
2020
- 2020-03-20 CN CN202010203820.6A patent/CN111388670A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784979A (en) * | 2014-01-17 | 2014-05-14 | 福州市传染病医院 | AntiGPC3-PB NPs (antiglypican3-Prussian Blue Nanoparticles) for photothermal therapy and magnetic resonance imaging of liver cancer as well as preparation and application thereof |
CN108495931A (en) * | 2015-11-11 | 2018-09-04 | 朱正崙 | A method of changing macrophage differentiation and is immunized |
CN110179837A (en) * | 2019-05-08 | 2019-08-30 | 天津大学 | The synthetic method of the visualization guidance tumour combined immunization treatment nanometer formulation of Gd:CuS mineralising influenza virus |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113633769A (en) * | 2021-01-11 | 2021-11-12 | 重庆医科大学 | Preparation method and application of lipopolysaccharide-loaded composite nanoparticles |
CN113633769B (en) * | 2021-01-11 | 2023-04-25 | 重庆医科大学 | Preparation method and application of lipopolysaccharide composite nanoparticle |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA010246B1 (en) | Activatable particles, preparation thereof and use | |
CN113493223A (en) | Preparation method and application of hollow manganese dioxide nanospheres | |
CN107638568B (en) | Biodegradable black phosphorus-based radiotherapy sensitizer and preparation method and application thereof | |
CN111388670A (en) | Synthesis method of mineralized Prussian blue-light immune preparation based on lipopolysaccharide | |
CN109549954B (en) | Phosphorus-based material preparation and preparation method and application thereof | |
CN111182926A (en) | Particles comprising bilirubin derivatives and metals | |
Wen et al. | On-demand phototoxicity inhibition of sensitizers and H2S-triggered in-situ activation for precise therapy of colon cancer | |
CN112220760A (en) | PH-responsive double-drug-loading system and preparation method and application thereof | |
CN112007170A (en) | Immunologic adjuvant functionalized metal organic framework material and preparation method and application thereof | |
Zhang et al. | Mild photothermal treatment sensitized immune checkpoint blockade therapy based on ATP-exhausted nanoenzymes | |
CN104784692A (en) | Method for preparing core-shell structure drug carrier with near-infrared light remote response and application thereof | |
Uthaman et al. | Light and immunostimulant mediated in situ re-education of tumor-associated macrophages using photosensitizer conjugated mannan nanoparticles for boosting immuno-photodynamic anti-metastasis therapy | |
TW202200116A (en) | Spiky metal organic framework, method for fabricating thereof, and test kit for cancer treatment | |
Gupta et al. | Leiomyosarcoma, a nonurothelial bladder tumor: a rare entity with therapeutic diversity | |
WO2023010776A1 (en) | Nano-drug having tumor immunity microenvironment regulation function, preparation method therefor, and application thereof | |
CN115737830A (en) | Hydrogel vaccine for inducing tumor immunogenic death and enhancing antigen presentation in space-time differentiation manner and preparation method and application thereof | |
CN115887693A (en) | Ferric tannate modified double photosensitizer loaded up-conversion nanoparticles, preparation method and application | |
CN105854034B (en) | The poly- amino-pyrroles composite nanoparticle diagnosis and treatment reagent of metal ion Copper-cladding Aluminum Bar, preparation method and applications | |
CN111558039A (en) | Method for synthesizing LPS @ CuS Gd photo-immunizing agent | |
CN114159588A (en) | Ternary alloy PtW-Mn-based nano probe, preparation method and application thereof | |
CN114309634B (en) | Preparation of gold quantum clusters and application of gold quantum clusters in gastrointestinal tract radiography and inflammation treatment | |
Li et al. | Nanocatalytic Anti‐Tumor Immune Regulation | |
WO2001028918A1 (en) | Controlled release of doxorubicin | |
EP1007519B1 (en) | Compounds for use in the treatment of cancer | |
CN106420661A (en) | Preparation method of hydroxyapatite/tannic acid composite particles capable of rapidly releasing ibuprofen in acidic solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200710 |